Pharmacotherapy of Acute Mania: Monotherapy or Combination Therapy with Mood Stabilizers and Antipsychotics?

Overview

Journal CNS Drugs

Specialties Neurology
Pharmacology

Date 2015 Feb 26

PMID 25711483

Citations 14

Authors

Iria Grande

Eduard Vieta

Affiliations

Soon will be listed here.

Abstract

The use of combination therapy with mood stabilizers and antipsychotics in acute mania in bipolar disorder (BD) is widespread, although most treatment guidelines recommend monotherapy as the first option, and reserve combination therapy, which is associated with more frequent and more severe side effects, for when patients do not respond to the former treatment option. Reasons to prescribe combination therapy include the lack of efficacy of the current treatment (either real or due to undisclosed poor adherence), psychiatric comorbidities, severe previous course of illness, slow cross-tapering during treatment switching, and potential benefits from particular combinations. The decision to start with monotherapy or combination therapy may depend on the patient characteristics, and is still under debate. Clinical trials designed to ascertain whether combination therapy or monotherapy is more advantageous for patients in acute mania and beyond, according to illness severity, are urgently needed. Adding a third monotherapy arm to the conventional two-arm, adjunctive-design trials or initiating combination therapy from the beginning may help to shed some light on the issue.

Citing Articles

New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview.

Bortolozzi A, Fico G, Berk M, Solmi M, Fornaro M, Quevedo J Pharmacol Rev. 2024; 76(3):323-357.

PMID: 38697859 PMC: 11068842. DOI: 10.1124/pharmrev.120.000007.

Fourteen-year trends in prescribing patterns for patients with bipolar mania discharged from a public psychiatric hospital in Taiwan.

Chiu H, Shih Y, Lin C Medicine (Baltimore). 2024; 103(9):e37270.

PMID: 38428897 PMC: 10906621. DOI: 10.1097/MD.0000000000037270.

Comparison of Aripiprazole and Risperidone effectiveness in treating obsessive-compulsive disorder in patients with bipolar disorder: Double-blind, randomized clinical trial.

Khorshidian F, Hamidia A, Kheirkhah F, Moghadamnia A, Bijani A, Mirtabar S Health Sci Rep. 2023; 6(8):e1531.

PMID: 37645033 PMC: 10460930. DOI: 10.1002/hsr2.1531.

Current and future directions of drug delivery for the treatment of mental illnesses.

Brewster P, Mohammad Ishraq Bari S, Walker G, Werfel T Adv Drug Deliv Rev. 2023; 197:114824.

PMID: 37068660 PMC: 11479664. DOI: 10.1016/j.addr.2023.114824.

Korean Medication Algorithm Project for Bipolar Disorder 2022, Fifth Revision: An Executive Summary.

Woo Y, Bahk W, Jeong J, Lee J, Kim W, Sohn I Clin Psychopharmacol Neurosci. 2022; 20(4):747-761.

PMID: 36263649 PMC: 9606436. DOI: 10.9758/cpn.2022.20.4.747.

References

Perlis R, Welge J, Vornik L, Hirschfeld R, Keck Jr P . Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2006; 67(4):509-16. DOI: 10.4088/jcp.v67n0401. View

Tohen M, Bowden C, Smulevich A, Bergstrom R, Quinlan T, Osuntokun O . Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry. 2008; 192(2):135-43. DOI: 10.1192/bjp.bp.107.041301. View

Murru A, Colom F, Nivoli A, Pacchiarotti I, Valenti M, Vieta E . When should mood stabilizers be withdrawn due to lack of efficacy? Some methodological considerations. Eur Psychiatry. 2011; 26(3):183-6. DOI: 10.1016/j.eurpsy.2010.09.012. View

Yatham L, Kennedy S, Parikh S, Schaffer A, Beaulieu S, Alda M . Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2012; 15(1):1-44. DOI: 10.1111/bdi.12025. View

Moller H, Kissling W, Riehl T, Bauml J, Binz U, Wendt G . Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. Prog Neuropsychopharmacol Biol Psychiatry. 1989; 13(1-2):127-36. DOI: 10.1016/0278-5846(89)90009-2. View

Sachs G, Peters A, Sylvia L, GRUNZE H . Polypharmacy and bipolar disorder: what's personality got to do with it?. Int J Neuropsychopharmacol. 2013; 17(7):1053-61. DOI: 10.1017/S1461145713000953. View

Szegedi A, Calabrese J, Stet L, Mackle M, Zhao J, Panagides J . Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol. 2011; 32(1):46-55. DOI: 10.1097/JCP.0b013e31823f872f. View

Sachs G, Grossman F, Ghaemi S, Okamoto A, Bowden C . Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002; 159(7):1146-54. DOI: 10.1176/appi.ajp.159.7.1146. View

Yildiz A, Vieta E, Leucht S, Baldessarini R . Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2010; 36(2):375-89. PMC: 3055677. DOI: 10.1038/npp.2010.192. View

10.

Torrent C, Amann B, Sanchez-Moreno J, Colom F, Reinares M, Comes M . Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008; 118(1):4-18. DOI: 10.1111/j.1600-0447.2008.01204.x. View

11.

Goikolea J, Colom F, Capapey J, Torres I, Valenti M, Grande I . Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. Eur Neuropsychopharmacol. 2012; 23(4):305-16. DOI: 10.1016/j.euroneuro.2012.05.017. View

12.

Tohen M, Chengappa K, Suppes T, Zarate Jr C, Calabrese J, Bowden C . Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002; 59(1):62-9. DOI: 10.1001/archpsyc.59.1.62. View

13.

Garfinkel P, Stancer H, Persad E . A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Disord. 1980; 2(4):279-88. DOI: 10.1016/0165-0327(80)90029-4. View

14.

Muller-Oerlinghausen B, Retzow A, Henn F, Giedke H, Walden J . Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol. 2000; 20(2):195-203. DOI: 10.1097/00004714-200004000-00012. View

15.

Sachs G, Chengappa K, Suppes T, Mullen J, Brecher M, Devine N . Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2004; 6(3):213-23. DOI: 10.1111/j.1399-5618.2004.00115.x. View

16.

Ketter T . Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. J Clin Psychiatry. 2009; 69 Suppl 5:9-15. View

17.

Nivoli A, Murru A, Goikolea J, Crespo J, Montes J, Gonzalez-Pinto A . New treatment guidelines for acute bipolar mania: a critical review. J Affect Disord. 2011; 140(2):125-41. DOI: 10.1016/j.jad.2011.10.015. View

18.

Scherk H, Pajonk F, Leucht S . Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007; 64(4):442-55. DOI: 10.1001/archpsyc.64.4.442. View

19.

Sachs G, Gardner-Schuster E . Adjunctive treatment of acute mania: a clinical overview. Acta Psychiatr Scand Suppl. 2007; (434):27-34. DOI: 10.1111/j.1600-0447.2007.01056.x. View

20.

Popovic D, Reinares M, Goikolea J, Bonnin C, Gonzalez-Pinto A, Vieta E . Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol. 2011; 22(5):339-46. DOI: 10.1016/j.euroneuro.2011.09.008. View